Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice

Background: A drug and disease assessment model was used to evaluate the impact of different treatment regimens on intravitreal ranibizumab, bevacizumab, aflibercept, and brolucizumab concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF. Methods: A time-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Veritti, Daniele, Sarao, Valentina, Gorni, Gianluca, Lanzetta, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877911/
https://www.ncbi.nlm.nih.gov/pubmed/35213999
http://dx.doi.org/10.3390/pharmaceutics14020265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877911/
https://www.ncbi.nlm.nih.gov/pubmed/35213999
http://dx.doi.org/10.3390/pharmaceutics14020265

Ejemplares similares